Pharmacology

Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)

Retrieved on: 
Monday, July 6, 2020
Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Euronext, Pharmacology

Pierre Broqua, CSO and cofounder of Inventiva, stated: We are very pleased with this decision following the positive results of lanifibranor during the Phase IIb clinical trial in NASH.

Key Points: 
  • Pierre Broqua, CSO and cofounder of Inventiva, stated: We are very pleased with this decision following the positive results of lanifibranor during the Phase IIb clinical trial in NASH.
  • Type 2 diabetes patients with NASH are generally exposed to an increased risk of poor clinical outcomes and are therefore in a critical need for an efficacious NASH treatment.
  • Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
  • Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA ISIN: FR0013233012).

Adamis Pharmaceuticals Provides Update on SYMJEPI Products

Retrieved on: 
Wednesday, July 1, 2020
Health, Pharmaceutical industry, Pharmacology, Pharmacy, Epinephrine, Injection

SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (USWM or US WorldMeds) began promoting Adamis SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products through its field sales force.

Key Points: 
  • SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (USWM or US WorldMeds) began promoting Adamis SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products through its field sales force.
  • Dr. Dennis J. Carlo, President and CEO of Adamis, said, We are very excited that US WorldMeds is now actively promoting both SYMJEPI products.
  • Adamis has always believed that sales reps calling on high-prescribing allergists and primary care physicians was key to the success of SYMJEPI.
  • In May 2020, the company acquired commercial rights to Adamis SYMJEPI products in the U.S. market.

Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials

Retrieved on: 
Tuesday, June 30, 2020
Health, Pharmaceutical industry, Pharmacology, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Medication

We believe we have taken the appropriate steps to ensure the safety of clinical trial participants and caregivers and we remain grateful for their commitment to our important clinical work.

Key Points: 
  • We believe we have taken the appropriate steps to ensure the safety of clinical trial participants and caregivers and we remain grateful for their commitment to our important clinical work.
  • The Company expects to complete enrollment in August of 2020, with topline data available in the first quarter of 2021.
  • Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.
  • Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

Catalent Expands Beauty and Plant-Based Consumer Health Softgel Capabilities at its Facilities in Canada and Brazil

Retrieved on: 
Tuesday, June 30, 2020
Dosage forms, Pharmacology, Health, Catalent, Pharmaceutical sciences, Softgel, Capsule

The expansion projects include new softgel encapsulation lines at each site, dedicated to Catalent's proprietary Vegicaps plant-based capsule and CosmoPod twist-off capsule technologies.

Key Points: 
  • The expansion projects include new softgel encapsulation lines at each site, dedicated to Catalent's proprietary Vegicaps plant-based capsule and CosmoPod twist-off capsule technologies.
  • "We have seen increased consumer demand for greater product choice, with sales of plant-based softgel technologies growing by more than 25% globally in recent years.
  • Additionally, Brazil has grown to become the world's fourth-largest market for beauty care products," commented Dr. Aris Gennadios, President, Softgel & Oral Technologies, Catalent.
  • Catalent partners with 23 of the top 25 consumer health companies and produces more than 5,000 consumer health and beauty products, which are marketed in more than 70 countries.

CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design

Retrieved on: 
Tuesday, June 30, 2020
Health, Food and Drug Administration, Design of experiments, Clinical research, Clinical trial, Pharmaceutical industry, Pharmacology

"We are extremely excited to have Berry Consultants, a renowned clinical statistical consulting company, advise on our Phase 2 trial design," commented John Climaco, Chief Executive Officer of CNS.

Key Points: 
  • "We are extremely excited to have Berry Consultants, a renowned clinical statistical consulting company, advise on our Phase 2 trial design," commented John Climaco, Chief Executive Officer of CNS.
  • "We believe the company's unparalleled expertise and innovative approach to clinical trial design will prove invaluable in the construction of our Phase 2 trial for Berubicin.
  • Berry Consultants employs world renowned experts in Bayesian statistics and strives to set the standard for innovative clinical trial design and analysis in the statistical and medical communities.
  • In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.

BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL

Retrieved on: 
Tuesday, June 30, 2020
Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Pharmacology

It will also investigate the expression of potential immunological markers that might be associated with clinical responses.

Key Points: 
  • It will also investigate the expression of potential immunological markers that might be associated with clinical responses.
  • It will be conducted at several sites across Europe and the U.S. and is expected to enroll approximately 120 patients.
  • Two preclinical programs in solid tumors are expected to enter clinical trials by the end of 2020.
  • With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL

Retrieved on: 
Tuesday, June 30, 2020
Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Pharmacology

It will also investigate the expression of potential immunological markers that might be associated with clinical responses.

Key Points: 
  • It will also investigate the expression of potential immunological markers that might be associated with clinical responses.
  • It will be conducted at several sites across Europe and the U.S. and is expected to enroll approximately 120 patients.
  • Two preclinical programs in solid tumors are expected to enter clinical trials by the end of 2020.
  • With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Peripheral Vascular Disease (PVD): Global Epidemiology, Market Analysis (2019-2024), Regional Statistics, Therapeutic Devices, and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 30, 2020
Medical devices, Health, Pharmacology, Health sciences, Health, Routes of administration, Dosage forms, Pharmacokinetics, Transdermal patch, Route of administration, Interventional cardiology, Dermal patch, Transdermal, Cardiology

The "Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices" report has been added to ResearchAndMarkets.com's offering.
  • In 2019, global sales of transdermal patch products targeting the conditions covered by this analysis totaled nearly $4.9bn, and is expected to increase at a CAGR of 2.4% over the forecast period, reaching $5.5bn in 2024.
  • Market drivers include the increasing prevalence of CVD and other associated disorders as the population ages, and improved patient compliance with patch-based pharmacology compared to oral medication.
  • Limiters include declines in mature market segments, and strong competition from oral pharmaceuticals and generic equivalents.

Global Oncology Drugs Market Outlook 2020-2030: COVID-19 Impact and Recovery Assessment - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 30, 2020
Professional services, Consulting, Health, Articles, Pharmaceutical industry, Pharmacology, Pharmacy, Pharmaceuticals policy

The "Oncology Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
  • It places the market within the context of the wider oncology drugs market, and compares it with other markets.
  • North America was the largest region in the global oncology drugs market, accounting for 35% of the market in 2019.
  • It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast.

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

Retrieved on: 
Monday, June 29, 2020
Biotechnology, Pharmacology, Proteolysis targeting chimera, Insulin-degrading enzyme

NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors.

Key Points: 
  • NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors.
  • We are pleased to welcome Wendy to Arvinas Board of Directors and look forward to her valuable insight related to key functions such as marketing, strategic planning, and business development, said John Houston, Ph.D., President and Chief Executive Officer at Arvinas.
  • Wendy is joining Arvinas at a very exciting time as we continue to grow and accomplish milestones that bring us closer to our mission of offering therapeutic options to patients who have few or none.
  • Arvinas is leading the way in targeted protein degradation and has already proven the concept of their proprietary PROTAC platform, added Dr. Dixon.